Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
4D Molecular Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing targeted genetic medicines using adeno-associated virus (AAV) vectors. The company operates within the biotechnology and gene therapy industries, with a strategic emphasis on precision-designed vectors for specific tissues. Its core mission is to improve the therapeutic index of gene therapies by enhancing delivery efficiency, durability, and safety.
The company’s primary revenue drivers are its gene therapy development programs, primarily in ophthalmology and pulmonology, and collaboration and license revenue from strategic partnerships. 4D Molecular Therapeutics serves patient populations with serious or chronic diseases, particularly those with retinal and pulmonary conditions. Founded in 2013, the company originated as 4D Therapeutics, Inc. and later rebranded as 4D Molecular Therapeutics to reflect its platform-driven focus. It completed its initial public offering in 2020 and is publicly traded on the NASDAQ under the ticker FDMT.
Business Operations
4D Molecular Therapeutics conducts its operations through a single integrated business model centered on its proprietary Therapeutic Vector Evolution Platform, which is used to engineer tissue-targeted AAV vectors. The company generates revenue primarily through research collaborations, licensing agreements, and potential milestone payments, as its internal pipeline remains largely in clinical development rather than commercialized.
Operationally, the company manages both domestic and international clinical activities, including preclinical research, manufacturing oversight, and clinical trial execution. Key assets include its internally developed vector libraries and intellectual property portfolio. The company has entered into major partnerships with Roche, Astellas Pharma, and UniQure, which provide non-dilutive capital and external validation of its platform technology.
Strategic Position & Investments
The company’s strategic direction centers on advancing wholly owned clinical programs while monetizing its platform through selective partnerships. Its lead internal candidates include ophthalmology programs targeting inherited retinal diseases and pulmonary programs addressing cystic fibrosis and other lung disorders. Growth initiatives focus on expanding the application of its vector platform into additional tissues and indications.
Major strategic investments include long-term collaboration agreements with Roche for ophthalmology-focused gene therapies and Astellas Pharma for ocular and non-ocular indications. The company has not pursued large-scale acquisitions but has invested heavily in internal R&D infrastructure and clinical manufacturing capabilities. Emerging areas of focus include next-generation AAV capsids and repeat-dosing strategies.
Geographic Footprint
4D Molecular Therapeutics is headquartered in Emeryville, California, which serves as the center for its research, development, and corporate operations. The company’s clinical trials and research collaborations extend internationally, particularly across North America and Europe, reflecting the global nature of its partner networks and patient recruitment strategies.
While the company does not operate large commercial facilities outside the United States, its strategic influence is global through multinational partnerships and clinical programs conducted in multiple countries. International exposure is primarily driven by partner-led development activities and regulatory interactions outside the U.S.
Leadership & Governance
The company was founded by David Kirn, who played a key role in establishing its scientific vision and early strategy. Leadership emphasizes a platform-first approach, prioritizing precision medicine, disciplined capital allocation, and partnership-driven growth. Governance is overseen by a board with experience in biotechnology, pharmaceuticals, and capital markets.
Key executives include:
- David McBride – Chief Executive Officer
- Alexis Boyer – Chief Financial Officer
- Robert J. Askew – Chief Medical Officer
- Lori Lyons – Chief Legal Officer
- Tom Bramsen – Chief Technical Operations Officer
The leadership team’s strategic vision focuses on advancing differentiated gene therapies while managing risk through staged clinical development and external collaborations.